[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
February 22, 1995

Estrogen Replacement Therapy in Breast Cancer Survivors

Author Affiliations

The University of Texas M. D. Anderson Cancer Center Houston

JAMA. 1995;273(8):620. doi:10.1001/jama.1995.03520320027030

To the Editor.  —We wholeheartedly applaud the suggestion by Dr Cobleigh and colleagues1 that the role of ERT in the care of postmenopausal women with a history of breast cancer should be defined in a thoughtful and broad-minded manner through carefully designed prospective clinical trials. The realization that omission of the ERT option may no longer be appropriate for all women previously treated for breast cancer has led us to initiate such a prospective study, as the authors point out.2 During our interactions with postmenopausal women with prior diagnosis of breast cancer, both within our institution3 and in the community, we are impressed by their compelling descriptions of the deleterious effects of estrogen deficiency on their sense of well-being. The principle that no one medical intervention is ever appropriate for all individuals appears intuitively obvious but merits repetition. We would like to caution that neither ERT nor

First Page Preview View Large
First page PDF preview
First page PDF preview